Appropriateness of extending the intensive phase of treatment based on smear results

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 1, 2004, Pages 114-116

  Enarson, D A ^a   Jindani, A ^a   Kuaban, C ^b   Lamothe, F ^c   Louissaint, M ^c   Ottmani, S E ^d   Ramarokoto, H ^e   Ridderhof, J C ^f   Urbanczik, R ^g  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b National Tuberculosis Control Programme   (Cameroon)

^c National Reference Laboratory for TB   (Haïti)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e National Tuberculosis Programme   (Madagascar)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

CLINICAL TRIAL; HUMAN; LETTER; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SPUTUM SMEAR; TREATMENT FAILURE; TREATMENT PLANNING; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SPUTUM; TIME FACTORS; TUBERCULOSIS, PULMONARY;

EID: 1642475496     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (21)

1. Pio A, Chaulet P. Tuberculosis Handbook. WHO/TB/98.253. Geneva, Switzerland: WHO, 1998.
2. Rieder H L, Sputum smear conversion during directly observed treatment for tuberculosis. Tubercle Lung Dis 1996; 77: 124-129.
3. Zhao Feng-zeng, Levy M H, Wen Sumin. Sputum microscopy results at two and three months predict outcome of tuberculosis treatment. Int j Tuberc Lung Dis 1997; 1: 570-572.
4. Wilkinson D, Bechan S, Connolly C, Standing E, Short G M. Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? Int J Tuberc Lung Dis 1998; 2: 52-55.
5. Trébuq A, Rieder H L. Two excellent management tools for national tuberculosis programmes: history of prior treatment and sputum status at two months. Int J Tuberc Lung Dis 1998; 2: 184-186.
6. Salaniponi F M L, Christensen J J, Gausi F, Kwanjana J J, Harries A D. Sputum smear status at two months and subsequent treatment outcome in new patients with smear-positive pulmonary tuberculosis. Int j Tuberc Lung Dis 1999; 3: 1047-1048.
7. World Health Organization. WHO Report 2002, Global Tuberculosis Control. WHO/CDS/TB/2002.295. Geneva, Switzerland: WHO, 2002.
8. Bwire R, Borgdorff M W, Sticht-Groh V, et al. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in Southern Uganda. East Afr Med J 1999; 76: 307-313.
9. Sundaram W, Fujiwara P I, Driver C R, Osahan S S, Munsiff S S. Yield of continued monthly sputum evaluation among tuberculosis patients after culture conversion. Int J Tuberc Lung Dis 2002; 6: 238-245.
10. Al-Moamary M S, Black W, Bessuille E, Elwood R K, Vedal S. The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis. Chest 1999; 116: 726-731.
11. East African/British Medical Research Council. Controlled clinical trial of five short course (4 months) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. Am Rev Respir Dis 1981; 123: 165-170.
12. Taik Chae Kim, Blackman R S, Heatwole K M, Taeho Kim, Rochester D F. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Prevalence and significance of negative smears pre-treatment and positive smears post-treatment. Am Rev Respir Dis 1984; 129: 264-268.
13. Ramarokoto H, Randriamiharisoa H, Rakotoarisaonina A, et al. Bacteriological follow-up of tuberculosis treatment: a comparative study of smear microscopy and culture results at the second month of treatment. Int J Tuberc Lung Dis 2002; 6: 909-912.
14. Telzak E E, Fazal B A, Pollard C L, Turett G S, Justman J E, Blum S. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clin Infect Dis 1997; 25: 666-670.
15. Gupta N. Persistent presence of acid-fast bacilli in pulmonary tuberculosis. Possible implications for developing countries. Communications to the Editor. Chest 2000; 118: 880-881.
16. Tam C M, Chan S L, Kam K M, Goodall R L, Mitchison D A. Rifapentin and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis 2002; 6: 3-10.
17. Devadatta S, Radhakrishna S, Fox W, et al. Comparative value of sputum smear examination and culture examination in assessing the progress of tuberculous patients receiving chemotherapy. Bull World Health Organ 1966; 34: 573-587.
18. Van Deun A, Portaels F. Limitations and requirements for quality control of sputum smear microscopy for acid-fast bacilli. Int J Tuberc Lung Dis 1998; 2: 756-765.
19. Aziz M, Bretzel G. Use of standardized checklist to assess peripheral sputum smear microscopy laboratories for TB diagnosis in Uganda. Int J Tuberc Lung Dis 2002; 6: 340-349.
20. Newman R, Doster B, Murray F J, Ferebee S. Rifampin in initial treatment of pulmonary tuberculosis. A US Public Health Service trial. Am Rev Respir Dis 1971; 103: 461-476.
21. Desjardin L E, Perkins M D, Wolski K, et al. Measurements of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med 1999; 160: 203-210.